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Abstract
Background: We previously showed that newborns congenitally infected with Trypanosoma cruzi (M+B+) display a strong
type 1 parasite-specific T cell immune response, whereas uninfected newborns from T. cruzi-infected mothers (M+B2) are
prone to produce higher levels of proinflammatory cytokines than control neonates (M2B2). The purpose of the present
study was to determine if such fetal/neonatal immunological environments could alter the response to standard vaccines
administered in early life.
Methodology: Infants (6–7 months old) living in Bolivia, an area highly endemic for T. cruzi infection, and having received
Bacillus Calmette Guerin (BCG), hepatitis B virus (HBV), diphtheria and tetanus vaccines, were enrolled into the M+B+,
M+B2,M 2B2 groups mentioned above. The production of IFN-c and IL-13, as markers of Th1 and Th2 responses
respectively, by peripherical blood mononuclear cells stimulated with tuberculin purified protein derivative of
Mycobacterium tuberculosis (PPD) or the vaccinal antigens HBs, diphtheria toxoid (DT) or tetanus toxoid (TT), as well as
circulating levels of IgG antibodies against HBsAg, DT and TT were analyzed in infants. Cellular responses to the
superantigen SEB were also monitored in M+B+,M +B2,M 2B2infants and newborns.
Principal Findings: M+B+ infants developed a stronger IFN-c response to hepatitis B, diphtheria and tetanus vaccines than
did M+B2 and M2B2 groups. They also displayed an enhanced antibody production to HBsAg. This was associated with a
type 1-biased immune environment at birth, since cells of M+B+ newborns produced higher IFN-c levels in response to SEB.
M+B2 infants produced more IFN-c in response to PPD than the other groups. IL-13 production remained low and similar in
all the three groups, whatever the subject’s ages or vaccine status.
Conclusion: These results show that: i) both maternal infection with T. cruzi and congenital Chagas disease do not interfere
with responses to BCG, hepatitis B, diphtheria and tetanus vaccines in the neonatal period, and ii) the overcoming of
immunological immaturity by T. cruzi infection in early life is not limited to the development of parasite-specific immune
responses, but also tends to favour type 1 immune responses to vaccinal antigens.
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Introduction
Infectious diseases are a leading world-wide cause of morbidity
and mortality in childhood, against which vaccination remains the
best prevention measure [1]. However, protection induced by
vaccines is of limited effectiveness in early life owing to the relative
immaturity of the neonatal immune system. Moreover, the fetal/
neonatal immune system is initially polarized toward a Th2
immune environment which appears essential for the survival of
the fetus [2,3]. Indeed, both dendritic cells and T cells present
quantitative and qualitative defects in the neonatal period, limiting
the development of CD4+ Th1 cell responses essential for the
control of intra-cellular pathogens [2,3], as well as the production
of antibody responses [4]. Nonetheless, neonates are in some cases
able to develop mature T cell responses. This has been
demonstrated in congenital infections with Trypanosoma cruzi [5]
and cytomegalovirus (CMV) [6], in infection with Bordetella pertussis
in early life [7], and after early vaccinations with Bacillus Calmette-
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Additionally, BCG vaccination at birth has been shown to increase
both cellular and humoral responses to other vaccines such as
hepatitis B and poliomyelitis vaccines [10]. Active maternal
infections may also modulate neonatal immune responses to
vaccines, as demonstrated in newborns of mothers chronically
infected with helminths, who developed a Th2-biased response to
BCG vaccination, by contrast with those born to non-infected
mothers [11,12]. The modulation of immune responses to vaccines
in infants from mothers infected with intracellular parasites, and
having experienced such congenital infection has heretofore not
been investigated.
Chagas disease, or American trypanosomiasis, caused by the
protozoan parasite Trypanosoma cruzi, is a major cause of morbidity
and mortality in Latin America where 8–10 million people are
currently estimated to be infected [13]. It has also become an
important health issue in the United States and Europe due to
large-scale migration of Latin Americans over the last few decades
[14]. The parasite is primarily transmitted by insect vectors (in
endemic areas of Latin America), blood transfusion and
congenitally (in all areas) [15]. Even the frequency of transmission
by vectors and blood transfusion decreases as a result of vectorial
control programmes and improvement of blood bank screening,
mother-to-child transmission of T. cruzi presently cannot be
prevented and has thus become an important route of transmission
[16]. Recent estimations indicate that at least 15,000 newborns are
likely to be congenitally infected with T. cruzi each year in Latin
America [17] and 2,000 in North America [18]. In Europe, such
transmission also becomes a problem in migrants originating from
endemic countries [19–21]. In Bolivia, a highly endemic area for
Chagas disease, we have reported that 17% of pregnant women
are chronically infected with T. cruzi and that congenital
transmission occurs in 5 to 6% of the cases [22]. We have showed
that congenitally infected newborns develop a parasite-specific T
cell immune response comparable to that of adults [5] as well as
phenotypic and functional modifications of their NK cells [23]. On
the other hand, newborns of T. cruzi-infected mothers are prone to
produce higher levels of pro-inflammatory cytokines in compar-
ison to those born to non-infected mothers [24]. The present study
aimed to determine if such modifications of the immune
environment in infected or uninfected newborns of T. cruzi-
infected mothers could modulate immune responses to vaccines
administered at birth or in early life. Cellular and/or humoral
responses to BCG, hepatitis B virus (HBV), diphtheria and tetanus
vaccines were compared in infants living in Bolivia.
Methods
Patients and diagnosis of T. cruzi infection
Two different patient groups from Cochabamba (Bolivia) were
enrolled in this study: one of neonates (born at the German
Urquidi Maternity) and one of infants (6 to 7 months old; followed
at the Manuel Ascenci Villaroel paediatric Hospital and the
Viedma Universitary Hospital, UMSS). The scientific/ethic
committee of the Universidad Mayor de San Simon (UMSS)
approved the study, and informed written consent was obtained
from the mothers before blood collection. Maternal T. cruzi
infection was assessed by standard serological techniques. T. cruzi
infection in neonates and infants was diagnosed by detection of
parasites in umbilical cord or peripheral blood by microscopic
examination of heparinized microhematocrit tubes, or in some
cases by hemoculture, as previously described [16,22]. Congenital
infection was assessed at or close to birth for 28 neonates and 10
infants. For 3 other infants, T. cruzi infection was diagnosed later
on when they presented at 6–7 months old at the consultation.
Congenital infection was inferred because these infants lived in an
area free of vectorial transmission, had not travelled in endemic
areas, and had not received blood transfusion.
Three groups of neonates and infants were established:
congenitally-infected (M+B+); non-infected born to T. cruzi-
infected mothers (M+B2); and uninfected controls born to
uninfected mothers (M2B2). A total of 68 newborns and 60
infants were included in the study (M+B+: 28 newborns and 13
infants; M+B2: 19 newborns and 36 infants; M2B2:2 1
newborns and 11 infants).
Mothers of neonates and infants included in the study were all
asymptotic, even when infected with T. cruzi. They originate
from the same rural region surrounding Cochabamba and live in
similar socioeconomic environment. The sex ratio in all groups
of newborns or infants was similar (data not shown). Clinical
data of the newborn groups have been previously reported [22]
and Table 1 shows mean ages and weights at the time of blood
collection, as well as historical clinical data at birth, of newborn
and infant groups. At the time of blood collection, the infant age
in the 3 groups was comparable and M+B2 and M2B2 infants
were all asymptomatic. At birth, such infants had similar
APGAR scores and maturity parameters. However, M+B+
infants presented at birth slightly lower mean gestational age,
weight and APGAR scores; three of them showed one or two
symptoms known to be associated with congenital T. cruzi
infection (i.e., splenomegaly, anasarca and petechia). When
examined at 6 to 7 months, M+B+ infants were asymptomatic,
but had still slightly lower mean weight as compared to the other
infants.
Management of patients
As soon as the diagnosis of congenital T. cruzi infection was
established, treatment of infected neonates/infants (7–10 mg/kg/
day of benznidazole for 30 days, [22]) was proposed to the mother.
From the 13 M+B+ infants under study, 9 were treated within the
Author Summary
Vaccines are of crucial importance to prevent morbidity
and mortality due to infectious diseases in childhood. A
modulation of the fetal/neonatal immune system (consid-
ered immature) toward Th1 or Th2 dominance could
modify responses to vaccines administered in early life. T.
cruzi is the agent of Chagas’ disease, in Latin America
currently infecting about 2 million women at fertile ages
who are susceptible to transmitting the parasite to their
fetus. In previous studies we showed that T. cruzi-infected
mothers can induce a pro-inflammatory environment in
their uninfected neonates (M+B2), whereas congenitally
infected newborns (M+B+) are able to develop a pro-Th1
parasite-specific T cell response. In the present study, we
analysed the cellular and/or antibody responses to Bacillus
Calmette Guerin (BCG), hepatitis B birus (HBV), diphtheria
and tetanus vaccines in 6- to 7-month-old infants living in
Bolivia. M+B2 infants produced more IFN-c in response to
BCG, whereas M+B+ infants developed a stronger IFN-c
response to hepatitis B, diphtheria and tetanus vaccines
and enhanced antibody production to HBs antigen. These
results show that both maternal infection with T. cruzi and
congenital Chagas disease do not interfere with responses
to BCG, hepatitis B, diphtheria and tetanus vaccines in the
neonatal period and that T. cruzi infection in early life
tends to favour type 1 immune responses to vaccinal
antigens.
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months of age when blood was collected for the present
immunological study. One remained untreated since her mother
refused the treatment, and 3 were treated from 6–7 months old
onwards since the diagnosis of infection was not established
previously (see above). Cure was confirmed in treated cases by the
subsequent negative results of direct parasitological examination
(microhematocrit tubes) and T. cruzi serology. All M2B2 and
M+B2 infants presented with negative serology for T. cruzi at 6 to
7 months of age, indicating that they had not acquired the
infection after birth.
Vaccination programme
In accordance with the recommended Bolivian vaccination
programme, all newborns received the BCG vaccine (BCG, Serum
Institute of India Ltd) at birth by intradermic injection. Infants
were then vaccinated against diphtheria, tetanus, whooping cough,
hepatitis B and type B Haemophilus influenzae (Hib) by receiving
intramuscular injections of Tritanrix mixed with Hiberix (Glax-
oSmithkline Biologicals, Rixensart, Belgium) at the ages of 2, 4
and 6 months. At the same time, they also received the oral
vaccine against poliomyelitis (attenuated vaccine, trivalent OPV,
Sanofi Pasteur, Paris, France). Infants included in this study have
all received the BCG at birth. At the time of blood sampling,
53.5% of the infants had completed the vaccinal schedule (3 doses
of Tritanrix + Hiberix + OPV), the others having received 2 doses.
The proportion of infants having received the 3 doses was similar
in each group.
Collection of blood samples, cell isolation and in vitro
cultures
Cord blood (CB) and infant peripheral blood (PB) were
collected in sterile endotoxin-free heparinized tubes. Plasma was
stored at 220uC until use for determinations of antibody levels.
Mononuclear cells (CBMC and PBMC) were immediately isolated
by Nycoprep density gradient centrifugation (Nycomed Pharma
AS, Oslo, Norway). CBMC and PBMC (2610
6 cells/mL -
duplicates) were then cultured in RPMI containing 10% fetal calf
serum (Biowhittaker, Lonza, Verviers, Belgium), either alone to
measure spontaneous production of cytokines, or in the presence
of one of the following antigens: tuberculin purified protein
derivative of M. tuberculosis (PPD; 5 mg/mL; batch RT49, Statens
Seruminstitut, Denmark), diphtheria toxoid (DT; 10 mg/mL),
tetanus toxoid (TT; 10 mg/mL), or the surface S antigen of HBV
(HbsAg; 10 mg/mL). DT, TT and HbsAg were kindly provided by
GlaxoSmithkline Biologicals (Rixensart, Belgium). A positive
control for T lymphocyte stimulation was included by incubating
cells with the staphylococcal enterotoxin B (SEB; 10 ng/mL;
Sigma-Aldrich) activating non specifically T cells (superantigen).
After 6 days of culture at 37uCi n5 %C O 2 humidified air, cell
cultures were centrifuged and supernatants conserved at 270uC
for further cytokine analysis.
Cytokine determinations
IFN-c and IL-13 cytokine concentrations were used as markers
of Th1/Th2 responses, respectively. Cytokine levels were
measured in culture supernatants by ELISA using commercial
kits (IFN-c: antibody pairs and standard from Biosource,
Invitrogen, Merelbeke, Belgium; IL-13: ultrasensitive kit from
Bender Medsystems, VWR International, Leuven, Belgium).
Standards were non-glycosylated recombinant cytokines (Bio-
source and Bender Medsystems). Detection limits were 2 pg/mL
for IFN-c, and 1 pg/mL for IL-13. Spontaneous release of
cytokines by unstimulated cells was generally undetectable or very
low. In the latter case, cytokine concentration was subtracted
from levels obtained after stimulation with SEB or vaccine
antigens.
HbsAg, TT and DT-specific antibody determinations
IgG antibodies against HbsAg, DT and TT were measured in
plasma samples by ELISA using commercial kits (HbsAg:
Diasorin, Brussels, Belgium, DT and TT: Genzyme Virotech
GmbH, Ru ¨sselsheim, Germany). Results in international units (IU)
were derived from WHO standard sera provided with the kits.
Antibody concentrations above 10 IU/mL for hepatitis B, and 0.1
IU/mL for diphtheria and tetanus were considered to be
protective [25–27].
IgG sub-classes against HbsAg were measured by ELISA as
follow : Nunc Maxisorp plates (VWR) were coated with HbsAg
(GSK Biologicals) at a concentration of 1.5 mg/mL in PBS
overnight at 4uC. After blocking with 1% bovine serum albumin
(BSA) in PBS for 2h at 37uC, plasma samples were diluted in PBS
containing 0.3% BSA and 0.05% Tween 20 and incubated for 2h
at 37uC. Sample dilutions were 1/50 for IgG1 and 1/10 for other
IgG sub-classes. Mouse monoclonal antibodies specific for the Fc
fragment of each human IgG subclass (clones HP6001, HP6014,
I7260 and HP6050 for anti-IgG1, G2, G3 and G4 antibodies
respectively, Sigma-Aldrich, Bornem, Belgium) were diluted 1/
500, and then incubated for 1h at 37uC, followed by rat
monoclonal antibodies specific for mouse IgG coupled to
horseradish peroxidase (clone LO-MK-1, Imex, UCL, Brussels,
Table 1. Characterization of the cohorts of neonates and
infants.
Variable (mean6SD) M2B2 M+B2 M+B+
Neonates
a
N2 1 1 9 2 8
APGAR 1 min 7.960.5 8.260.6 7.761.5
APGAR 5 min 9.160.8 9.360.6 9.361.5
(p=0.059)
c
Gestational age 39.760.5 39.761.12 38.962.2
(p=0.052)
c
Birth weight (g) 33296355 33676305 30736385
(p=0.003)
c
Infants
a
N1 1 3 6 1 3
Age (days)
b 196621 192617 195614
APGAR 1 min 8.060.2 8.060.4 7.461.6
APGAR 5 min 9.360.5 9.460.5 8.960.9
(p=0.076)
c
Gestational age at birth 39.860.5 39.460.9 38.960.8
(p=0.044)
c
Birth weight (g) 33386335 31716436 29716459
(p=0.072)
c
Actual weight (g)
b 81606576 82586936 77576928
(p=0.060)
c
M+: T. cruzi infected mothers; M2: not infected mothers; B+: congenitally
infected with T. cruzi; B2: not infected.
aNumber of newborns or infants per group are indicated in Methods.
bAt the time of blood sampling.
cThe value of p compares congenital subjects to the 2 other groups together
(Mann-Withney U test) and is given when ,0.1.
doi:10.1371/journal.pntd.0000571.t001
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washed with PBS containing 0.05% Tween 20. Finally, substrate
and chromogen were added (hydrogen peroxide and 3,39, 5,59
te ´trame ´thylbenzidine, BD Biosciences, Erembodegem-Aalst, Bel-
gium) and absorbance at 450 nm was measured after 30 min
colour development and stopping the reaction with 2N sulphuric
acid. Positive and negative internal controls were added in each
ELISA plate in order to correct the absorbances for plate
variability. We found a very good correlation between the levels
of total HbsAg-specific IgG measured with this ELISA and those
obtained using the commercial Diasorin kit (r=0.842, p,10
24,
n=25). Absorbances lower than 0.01 were considered a negative
result.
Expression of results and statistical analysis
Results were expressed either as arithmetic means6SEM or
geometric means. Statistical comparisons of concentrations of
cytokine or antibody levels between groups of newborns or
infants were performed either with the Mann Whitney test or by
two-way analysis of variance (ANOVA), followed by Tukey test
for multiple comparisons. Comparisons of proportions were
carried out using the Fisher exact test. Statistical analyses were
conducted using GraphPad Prism software (GraphPad Prism 4,
San Diego, CA) or the Statistical Software Package SPSS
version17.0.
Results
Congenitally T. cruzi-infected newborns display a
polarized Th1 response to SEB
Fig. 1 shows that, upon SEB stimulation, cells from M+B+
newborns produced significantly more IFN-c in comparison with
the M2B2 neonate group (geometric means 4372 and 551 pg/
mL respectively). Interestingly, such congenitally infected neonates
displayed at birth comparable levels to those observed in controls
at 6–7 months (geometric means in M2B2 infants : 4726 pg/
mL). Meanwhile, IL-13 levels remained similar in all neonate
groups. Comparable results were seen in the M+B2 and M2B2
groups. This indicates that the in utero immune environment
associated with congenital Chagas disease induces an early shift in
the neonatal immune response toward a type 1 response.
Congenitally T. cruzi-infected infants present a Th1
shifted response to vaccines against diphtheria, tetanus
and HBV
IFN-c and IL-13 were not detected at birth when CBMC were
incubated with DT, TT and HbsAg vaccinal antigens. However,
as shown in Table 2, these cytokines were detected in 6 to 7 month
old infants. Two way Anova followed by a test for multiple
comparisons (Tukey) indicated that the IFN-c responses in the
different infant groups was not influenced by the used antigen
Figure 1. IFN-c and IL-13 productions in response to SEB by blood mononuclear cells from newborns and infants. Newborns and 6 to
7 months-old infants were born either to T. cruzi-infected (M+) or not infected mothers (M2), and either congenitally infected (B+) or not (B2). Cells
were cultured during 6 days in the presence of 10 ng/mL SEB (staphylococcal enterotoxin B). Results of cytokines levels measured by ELISA
(individual results and geometric means) are shown. * : p,0.05 and ** : p,0.005 (Mann-Withney U test).
doi:10.1371/journal.pntd.0000571.g001
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the results of each antigen. This showed IFN-c responses to
vaccinal antigens to be significantly higher in congenitally-infected
M+B+ infants as compared to each other groups (M+B+ vs.
M2B2 : p=0.007 ; M+B+ vs. M+B2 : p=0.0003) whereas they
were similar between M2B2 and M+B2 infants (p.0.05). Thus,
M+B+ infants produced meanly 10–12 times more IFN-c to HbS
and DT, and 3–4 times more of this cytokine in response to TT.
IL-13 release to these 3 vaccinal antigens did not differ between
groups. This highlights a trend towards a type 1 response for
vaccines against hepatitis, diphtheria and tetanus administered in
congenitally infected neonates. Since the benznidazole treatment
received by M+B+ infants before vaccination might have some
confounding effect on stimulating immune responses [28], data
were also analyzed separating treated and untreated infants (at the
time of blood collection). Similar results were observed in both
M+B+ subgroups (data not shown).
Congenitally T. cruzi-infected infants produce higher
antibody levels against HbsAg in response to HBV
vaccination
As indicated in Fig. 2, mean levels of IgG antibodies against the
vaccinal antigens HbsAg, DT, TT at birth were similar in the 3
groups of neonates, and high enough to be considered protective
(67 to 100% above the protection thresholds of 10 IU/mL for
hepatitis B, and 0.1 IU/mL for diphtheria and tetanus). This
indicates that mothers had been immunized and that the transfer
of such maternal antibodies during pregnancy was not affected by
T. cruzi infection.
In the 3 infant groups, HbsAg-specific antibody levels were
significantly higher than in newborns. This sustains HbsAg-specific
antibodies to be produced by the infants in response to
vaccination, although maternally transmitted antibodies may still
be present at low levels their sera [29]. Inversely, DT- and TT-
specific antibody levels were lower in infants than at birth,
suggesting that maternally transmitted antibodies may have
restricted their production [30]. Nevertheless, they are close to
antibody levels described by others in vaccinated infants [31].
Interestingly, M+B+ infants produced noticeably more antibody in
response to the vaccine against hepatitis than those of the other
groups. Though not statistically significant, a similar trend was
seen for the M+B+ DT- and TT IgG antibodies. For the reasons
mentioned above, M+B+ HbsAg-specific antibody levels were also
analyzed by separating treated and untreated infants, and, again,
results were similar in both M+B+ subgroups (data not shown).
Since the polarization of the immune response is known to
modulate the isotypes of antibodies produced [32–34], we next
determined the IgG subclass profile of the HbsAg-specific
antibodies in vaccinated M+B+ infants. As shown in Fig. 3 and
as expected from previous reports [35,36], IgG1 was the main
subclass of IgG antibody found in infants vaccinated against HBV
regardless of the group. Comparisons between groups show that
M+B+ infants harboured 2 to 4-fold higher levels of IgG1, IgG2
and IgG3 than infants of the other groups, while IgG4 levels
remained low in all groups. Such variations likely account for the
greater production of total HbsAg-specific IgG described above in
these M+B+ infants, likely reflecting their stronger type 1 immune
environment.
Uninfected infants born to T. cruzi-infected mothers
display an amplified type 1 response to PPD after BCG
vaccination
We also studied the Th1/Th2 cytokine responses to the BCG
vaccine by stimulating mononuclear cells with mycobacterial PPD.
CBMC (newborns) did not produce either IFN-c or IL-13 after
PPD stimulation, regardless of group (a total of 32 newborns were
tested). By contrast, PBMC from most infants having received the
BCG vaccine at birth produced cytokines in response to PPD
(Fig. 4). The proportions of IFN-c responders was $70% and
similar in the 3 infant groups. However, M+B2 but not M+B+
infants, produced on average 5-fold more IFN-c in response to
PPD in comparison to control M2B2 infants. IL-13 levels
produced by M+B2 infants in response to PPD were low, and the
proportion of IL-13 responders was slightly but significantly
inferior to that of both other groups. This suggests that, even in the
absence of congenital T. cruzi transmission, the maternal-fetal
immune environment associated with maternal infection contrib-
utes to enhance the Th1 response to the BCG vaccine
administered at birth.
Discussion
We have investigated the effect of congenital Chagas disease
and/or maternal T. cruzi infection on immune responses to
standard vaccines regularly administered in neonates and infants
in Bolivia. Our results show that: i) congenitally T. cruzi-infected
newborns (M+B+) display an early ability to produce the type 1
cytokine IFN-c; ii) their specific responses (M+B+) to the hepatitis
B vaccine, and to a lesser extend to diphtheria and tetanus
vaccines, administered later after birth are characterized by higher
levels of IFN-c and/or protective IgG antibodies; and iii) non-
infected infants born to T. cruzi–infected mothers (M+B2) secrete
higher amounts of IFN-c in response to BCG vaccination
administered at birth.
The responses to PPD that we observed in BCG-vaccinated
infants were Th1-oriented in the 3 studied groups. This agrees
with previous observations showing that BCG vaccine given at
birth induces a strong Th1 response that modulates the neonatal
Th2 immune environment, with the CD4+ subpopulation of T
cells being the main source of IFN-c [8,37]. However, M+B2
infants mounted a still stronger Th1 response to BCG. This likely
relates to the prenatal activation of the immune system induced by
maternal T. cruzi infection described by us and others, leading to a
non-specific activation of various cell types as monocytes,
lymphocytes and probably other cells [24,38]. Such activation
might result from the transplacental transfer of soluble molecules
Table 2. Production of IFN-c and IL-13 in response to vaccinal
antigens by PBMC from infants from mothers infected (M+)o r
not (M2),with T. cruzi, and congenitally infected (B+) or not
(B2).
Vaccinal Ag Infant group IFN-c (pg/mL)
a IL-13 (pg/mL)
a
HBsAg M2B2 22.262.6 10.164.6
M+B2 18.566.3 37.2631.1
M+B+ 2216151 19.2617
Diphtheria toxoid M2B2 27.360.4 6.260.5
M+B2 40.5624.6 59.9651.4
M+B+ 3546158 12.968.8
Tetanus toxoid M2B2 58.3624.7 8.466.0
M+B2 107642 20.966.7
M+B+ 205694 20.5611.4
aArithmetic mean6SEM.
doi:10.1371/journal.pntd.0000571.t002
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Tc52 molecule known to activate directly dendritic cells or pro-
inflammatory glycophosphatidyl-inositol anchors [39–41]. Our
study shows that chronic maternal infection with an intracellular
pathogen can influence the neonatal immune environment
sufficiently to enhance the Th1 regular infant response to BCG.
Figure 2. Antibody levels against hepatitis B, diphtheria and tetanus vaccines in newborns and infants. Plasma levels of specific IgG in
newborns and 6 to 7 months old infants born to mothers infected (M+) or not (M2) with T. cruzi, and congenitally infected (B+) or not (B2), and
vaccinated at 2, 4 and 6 months against hepatitis B, diphtheria and tetanus. Results are shown as geometric means; extreme values are indicated, as
well as the proportion of samples showing an antibody level above the indicated threshold of protection. * : p,0.05 (Mann Withney U test).
doi:10.1371/journal.pntd.0000571.g002
T. cruzi Infection and Infant Response to Vaccines
www.plosntds.org 6 December 2009 | Volume 3 | Issue 12 | e571This is also in line with other work showing, conversely, that
neonates born to mothers chronically infected by helminths,
known to promote Th2 immune responses, display diminished
responses to PPD [11,12,42].
By contrast, M+B+ infants failed to exhibit an increased
response to BCG vaccine. This is surprising, since they presented
at birth, when BCG was administered, a marked type 1 immune
bias (indicated by their increased IFN-c response to SEB), and
harboured high amounts of circulating live parasites [43],
susceptible to release the pro-inflammatory molecules mentioned
above. Different hypotheses could explain such divergence
between M+B2 and M+B+ infant responses to BCG. First, the
treatment received by M+B+ infants might have contributed to
modify their response; the similar PPD responses observed in
treated and untreated infants may not rule out a treatment effect
since the number of cases in each subgroup was low. The M+B+
IFN-c2producing T cells might also have been temporary
exhausted as indicated by their high level of apoptosis resulting
from their intense response to parasite multiplication [5],
subsequently limiting the responses to other antigens, as also
shown in other infections [44,45]. Another possibility relates to the
higher frequency of prematurity and low birth weights in the
M+B+ newborn group [22], known to reinforce immune
immaturity [46,47]. Furthermore, congenital T. cruzi infection
might have down-regulated the cord blood T cell response, as
observed in malaria [48]. Finally, it is also possible that the IFN-c
response to BCG increases earlier in M+B+ infants than in other
groups, and is no more detected at 6–7 months, in agreement with
the observation that there is no more difference in the response to
SEB between groups at 6–7 months.
Nevertheless, the immune responses of M+B+ infants to
hepatitis B vaccine, and to a lesser extend against diphtheria
and tetanus vaccines, given after birth, were stronger and more
type 1-oriented than in both of the other groups of uninfected
infants. This group produced significantly higher specific IgG
levels in response to HBV vaccine. A similar trend was observed
for antibody responses to diphtheria and tetanus vaccines.
Enhanced antibody responses in M+B+ infants were associated
with increased IFN-c production in response to vaccine antigens.
The observation that, amongst the HbsAg-specific IgG, the IgG1,
IgG2 and IgG3 subclasses, known to be associated with type 1-
responses to intracellular pathogens [32–34] were increased still
emphasizes the Th1-biased profile of the response. The mecha-
nism of such type 1-shift of the immune response to DT, TT and
HBV vaccines associated with congenital Chagas disease, and why
it is not observed in M+B2 infants, remains to be elucidated.
Some non-exclusive factors might be considered. First, the fact
that the immunological modulation observed at birth in M+B2
newborns is transient [38] could imply that it could have a short
term impact on immune responses to vaccines given from 2
months of age onwards. Secondly, the benznidazole treatment
received by M+B+ infants might release parasitic pro-inflamma-
tory molecules (see above) from lysed parasites favouring IFN-c
production [28]. However, high parasite levels were no longer
present at the time of diphtheria, tetanus and HBV vaccine
administration (2, 4 and 6 months). No differences in the IgG and
Figure 3. Levels of antibody IgG sub-classes against hepatitis B
in vaccinated infants. Plasma levels of HbsAg-specific IgG sub-classes
in 6 to 7 months old infants born to mothers infected (M+) or not (M2)
with T. cruzi, and congenitally infected (B+) or not (B2), and vaccinated
at 2, 4 and 6 months against hepatitis B. Results are displayed as box
and whiskers (n=6 M2B2,1 3M +B2 and 9 M+B+). * : p,0.05
compared with infants from other groups (Man Withney U test).
doi:10.1371/journal.pntd.0000571.g003
Figure 4. Cytokine response to PPD in infants vaccinated with BCG. IFN-c and IL-13 production in response to tuberculin purified protein
derivative of M. tuberculosis (PPD) by PBMC from 6 to 7 months old infants born to mothers infected (M+) or not (M2) with T. cruzi, and congenitally
infected (B+) or not (B2), and having received at birth the BCG vaccine. PBMC were cultured during 6 days in the presence of 10 mg/mL PPD. Results
of cytokines levels measured by ELISA are shown (individual results and geometric means). The proportions of responders (i.e. showing detectable
levels of cytokines) are also shown. * : p,0.05 and ** : p=0.006 compared with M2B2 infants (Mann-Withney U test for means and Fisher test for
proportions).
doi:10.1371/journal.pntd.0000571.g004
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between treated and untreated infants, suggesting that treatment
has a minimal effect on the Th1 shift observed in M+B+ infants.
Third, the type of vaccine might also play a role on the different
responses between M+B+ and M+B2 infants. Indeed, BCG is a
cellular, live attenuated vaccine, meaning that non virulent
mycobacterias multiply in the host receiving the vaccine, which
induces mainly a T cell response (CD4+ Th1 and CD8+), whereas
the vaccines against hepatitis B, diphtheria and tetanus are
acellular vaccines eliciting mainly a B cell production of IgG
antibodies with the help of T cells. Our results suggest that at
birth, the immune environment in uninfected newborns from T.
cruzi-infected mothers (M+B2) favours preferentially a cellular
response, while that of congenitally-infected infants (M+B+)i s
more prone to modulate antibody responses.
If the increased competence to secrete IFN-c in both M+B2
and M+B+ infants might confer better or earlier protection against
infection may be discussed. Indeed, our study was limited to blood
samples collected from infants at 6–7 months of age. Earlier
sample collection would be useful for kinetic studies to appreciate a
possible earlier protective effect. A follow-up might also permit to
compare the functional implication of the protective effect of the
different vaccinations between infant groups. Though the response
to PPD does not correlate with protection against tuberculosis
[49], we may assume that it reflects a globally better response to
BCG, a vaccine known to limit the severity of tuberculosis if
acquired during early infancy, although it does not prevent the
acquisition of infection [50]. For the other vaccines, the fact that
M+B+ infants produce higher amounts of protective antibodies
suggests that protection is probably reached earlier in life in infants
suffering from congenital Chagas disease.
Although this study involved a limited number of cases, our
results show that both maternal infection with T. cruzi and
congenital Chagas disease have no major impediment on vaccinal
responses to BCG, hepatitis B, diphtheria and tetanus vaccines in
the neonatal period. Nevertheless, both conditions induced a trend
towards a type 1 immune polarization known to be essential in
fighting intracellular pathogens [3]. In addition, our results also
show that the overcoming of immunological immaturity by T cruzi
infection in early life is not limited to the development of parasite-
specific immune response [5], but has also effects on responses to
parasite-unrelated vaccinal antigens. This suggests adjuvant
properties of some T. cruzi molecules, offering new prospects in
neonatal vaccinology.
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